The company provides specialist HEOR services to pharmaceutical and medical device manufacturers — covering literature reviews, health economic modelling, and communications materials.
For the insurance sector, the business develops and supports underwriting models, facilitating a wide range of solutions.
Sales between the 1st April and the 31st October 2026 stand at just over £1 million, with £667,000 left to invoice.
Blue-chip client base, including top-tier global pharmaceutical companies, major UK insurers, pension providers and a global reinsurer.
10 active clients, all of which provide repeat business, with 100% of income under contract through master service agreements.
Proprietary, in-house developed online evidence screening and mapping platform, which is licensing-ready.
Multidisciplinary team of clinicians, actuaries and biomedical scientists, with low staff turnover.
YE26 management turnover of £1.5m, with an adjusted EBITDA of circa £233k.
Substantial increase in turnover and EBITDA from YE24-YE26.
Having built up a successful and highly respected business, our clients are offering the business for sale to facilitate retirement plans and to ensure further growth under the impetus of new ownership.
Offers invited.
